Statement of Translational Relevance
Metastasis to the central nervous system is common in advanced breast cancer. With limited treatment options available to patients with metastatic foci, we explored cellular and gene therapy approaches as potential treatments for breast cancer metastatic to brain. This report describes work to indicate the individual, and especially the combined immunogene treatment modalities are effective in vitro, and in in vivo xenograft models. These novel therapies are well tolerated, brain sparing and provide multiple mechanisms of tumor cell targeted cytotoxicity, including cytotoxic T lymphocyte effector-mediated and chemotherapeutic-mediated cytolysis with suicide vector/prodrug that may be further promoted with bystander effects. Preclinical studies of the individual treatment modalities have warranted their advance to the clinic for treatment of gliomas.
Those data and that within this study support accelerated translation of the therapies for treatment of brain metastases. 
INTRODUCTION
Breast cancer is the most common malignancy in women in the United States and metastasis is a major cause of morbidity and mortality in these patients. With improvements in the control of visceral and bone metastasis, the incidence of brain metastasis is rising (1) (2) (3) . The progressive neurological disabilities associated with brain metastasis not only impair the quality of life but also decrease the survival. The biology of the brain and blood brain barrier, and the fact that brain metastases can present as multiple lesions often characterized by nests of infiltrating tumor cells surrounding the larger brain metastases (4, 5) make the management of brain metastases very challenging. Currently therapeutic approaches include whole brain radiation therapy and stereotactic radiosurgery usually administered as palliative care (6) (7) (8) .
Newer approaches include the use of tumor-targeted cytotoxic T lymphocytes for adoptive immunotherapy. A unique form of adoptive T cell therapy for brain tumors involves the use of alloreactive cytotoxic T lymphocytes (alloCTL), potent cytotoxic T cell effectors that are trained to recognize non-or aberrant-self class I and II human leukocyte antigens (HLA). They are generated by sensitization of peripheral blood mononuclear cells (PBMC), isolated from a healthy donor, to the HLA of the tumor-bearing host (9) (10) (11) . The HLA primarily acts as tumor-directed antigen in the brain, since its expression, especially Class I, is absent on normal neuroglia, i.e., neurons, oligodendrocytes, and astrocytes (12) (13) (14) , but is highly expressed on brain tumor cells (13, (15) (16) (17) (18) .
Another new therapeutic approach is the use of replicating virus vectors for gene therapy or oncolytic virotherapy. Recently, it has been demonstrated that replicating retroviral vectors (RRV), unlike their replication-defective counterparts, exhibit sustained transduction in dividing cancer cells and can efficiently transfer transgenes throughout solid tumors (19) (20) (21) (22) (23) (24) . Gliomabearing rats demonstrate significantly prolonged survival when given RRV coding for the prodrug activator gene, yeast cytosine deaminase (CD) followed by multiple administrations of 5-fluorocytosine (5-FC) prodrug (20) (21) (22) . The lack of detectable spread of the RRV to normal tissues additionally provides an element of safety in this approach (21, 23, 25) .
Both alloCTL adoptive immunotherapy and RRV-mediated prodrug activator gene therapy have been studied individually in patients with primary brain tumors. Notably, the clinical feasibility and safety of intratumoral alloCTL treatment was initially tested in a small pilot study (9, 11) , in which three recurrent Grade III glioma patients receiving this treatment exhibited survival longer than expected. These data led to the initiation of a Phase I dose-escalation study at UCLA, now accruing patients (www.clinicaltrials.gov, NCT01144247). As well, RRV encoding CD for Clinically, brain metastases are more common than primary brain tumors (26) , and represent a dire clinical situation in need of effective therapies. Here, we evaluated both of these cellular and gene therapy approaches, individually and in combination, for the treatment of intracranial breast tumors. Our results demonstrate that alloCTL generated to the breast tumor cell line MDA-MB-231 (231) showed cytotoxicity, proliferation, and interferon-gamma (IFNγ) production in response to coincubation with the parental target cell line, as well as with two metastatic sublines (27, 28) .
Intracranially placed alloCTL were capable of migrating from one established intracranial tumor focus to another in contralateral brain over a relatively short time span (6 hr) in immuneincompetent mice, and apoptotic tumor cells were observed in proximity to these CTL. Using subcutaneous and intracranial human breast tumor xenograft models, we found that combining prodrug activating gene therapy with alloCTL adoptive transfer resulted in improved outcome compared to the benefit seen with each therapy individually. Our findings thus support clinical translation of this multi-modal approach.
MATERIALS AND METHODS

Cell lines and HLA expression.
The human breast tumor cell line MDA-MB-231 (231; ATCC, Manassas, VA) was grown in L15 medium supplemented with 10% fetal bovine serum (FBS; Aleken, Nash, TN). The brainseeking 231 subline, 231BR (27) , the bone-seeking 231 subline, 231-1833 (28) , and 293T human embryonic kidney cells (ATCC) were maintained in Dulbecco's modified Eagles medium (DMEM) supplemented with 10% FBS, sodium pyruvate and penicillin/streptomycin (Sigma, St.
Louis, MO). Class I HLA display was determined on breast cancer cell lines by flow cytometric analysis using RPE-conjugated mouse anti-human HLA-ABC antibody and a mouse RPEconjugated IgG served as isotype control (eBiosciences, San Diego, CA). The percentage of positive cells and relative antigen density indicated by mean fluorescence intensity (MFI) were determined (13) . Specific HLA-ABC types were determined by low resolution molecular HLA typing (University of California, San Diego, Torrey Pines Clinical Laboratory, San Diego, CA).
Generation of alloCTL enriched cultures by one-way mixed lymphocyte tumor reaction
Research. 
(MLTR).
PBMC were isolated from leukopaks of healthy donors undergoing leukapheresis (UCLA Institutional Review Board approved protocol) using density gradient centrifugation as previously described (10) . Prior to one-way MLTR, 231 cells underwent 48-hr incubation in culture medium with 500 IU/ml recombinant human IFNγ (RD Systems Inc., Minneapolis, MN) to upregulate their HLA expression (13) . The stimulator (S) 231 cell monolayers were then washed with phosphate buffered saline (PBS) and detached with 2 mM EDTA containing 1% BSA, washed and inactivated with 7000 rad (X-ray Irradiator, Gulmay Medical, Inc., Atlanta, GA). Responder (R) PBMC were mixed with inactivated S cells at a R:S ratio of 10:1. The cell mixtures were placed into Aim-V medium (Life Technologies, Inc., Grand Island, NY) containing 5% heat-inactivated autologous plasma and 60 International Units (IU) of recombinant human interleukin-2 (IL-2)/ml (Proleukin, Novartis, San Carlos, CA). Growth was monitored daily and cultures were fed and maintained as previously described (10) . AlloCTL preparations were used in assays between 12 to 14 days post-MLTR.
Plasmid constructs and viral vector production.
The pAC3-yCD2 and pAC3-GFP plasmid constructs, encoding amphotropic Moloney murine leukemia virus (MuLV) carrying expression cassettes consisting of an internal ribosome entry site (IRES) followed by either CD or green fluorescent protein (GFP) transgenes, respectively, have been described previously (23, 24) . Viral vector stocks were generated by transfection of 293T cells using the FuGENE6 transfection agent (Roche Molecular Biochemicals, Mannheim, Germany) per manufacturer instructions (22) . Conditioned medium (viral supernatant) was collected 48 hr after transfection with either the pAC3-GFP or pAC3-yCD2 plasmids (23, 24) .
Concentrated viral vector supernates were prepared from 293T stable vector producing cells.
Conditioned medium was harvested after 72-hr incubation, and clarified by centrifugation before 100-fold volume concentration using a Vivaspin-20 (Sartorius Stedim, Gottingen, Germany) per manufacturer protocol. Control supernatant from nontransduced, non-vector producing 293T cells was harvested and concentrated in parallel. Concentrated viral titers were approximately 10 6 transducing units/ml when tested using either 293T or 231BR cells. The titer was determined 48 hr after adding 50 µM of 3'-azido-deoxythymidine (AZT, Sigma Aldrich, St. Louis, MO) to the cultured cells to prevent further virus replication as described (20, 29) . For subcutaneous (sc) In vivo studies with human 231BR xenografts.
Rag2-/-γc-/-mice were purchased from Taconic Farms (Hudson, NY) (31) . All animal experiments were performed according to institutional guidelines under approved protocols. Table 1 Table 2 ).
AlloCTL exhibit anti-tumor function in vitro
The standard method for generating alloCTL is by one-way mixed lymphocyte reaction (MLR) where inactivated stimulator PBMC from the cancer patient are combined with responder PBMC from healthy donors genetically-distinct from the patient (10). However, because PBMC are not available from the patient from whom 231 breast tumor cells were derived, to generate alloCTL we used a one-way MLTR where 231 tumor cells were incubated with IFNγ to upregulate HLA Class I expression as above, then inactivated and used as stimulator cells with responder PBMC isolated from HLA-mismatched allogeneic donors (33) .
Four different donors provided PBMC that served as sources of precursor alloCTL for these experiments. All donors were mismatched at 4-5 class I HLA-ABC alleles compared to that displayed by the 231 stimulator cells (Supplemental Data Table 2 ). The HLA types of alloCTL used for in vitro and in vivo experiments are provided and associated with data in particular
Figures. Note these preparations will contain CTL directed to minor tumor associated antigens as well as HLA, albeit the precursor frequency for CTL within PBMC would be higher to major than to minor antigens (34) (35) (36) .
To determine if the alloCTL made by MLTR had anti-tumor function in vitro we performed cytotoxicity assays on day 14 following one-way MLTR. AlloCTL effector cells were mixed with 
in a dose-dependent manner, the ability of alloCTL to kill each of the three target cell lines was similar; there were no significant differences in the percentages of lysis obtained at each E:T ratio (Figure 1) . Furthermore, the cytolysis induced by alloCTL to 231 and its sublines is in part HLA- Figure 2D ).
Production was more robust when restimulation was performed with the parental cells versus the sublines, correlating with the relative antigen densities (MFIs) of cell-surface Class I HLA (Suppl Table 1 13.2 ± 0.97 ng/ml, respectively) was significantly elevated (p<0.017) compared to that of unstimulated alloCTL (7.4 ± 0.21 ng/ml).
alloCTL migrate through and to distant tumor foci in vivo and induce apoptosis.
We examined the migratory capacity of alloCTL in the context of multifocal intracranial tumors. Figure 3A , bilateral 231BR tumors were established intracranially in the right and left hemispheres of Rag2-/-γc-/-mice, and allowed to grow for 21 days. AlloCTL specific for 231 HLA were then stereotactically injected into the tumor bed on the right side ( Figure 3A) , and coronal sections of brain were prepared 6 hr later and immunostained with a human CD3-specific antibody (Figures 3B-G) . Figure 3B RRV can achieve significantly enhanced transduction compared to their replication defective counterparts (19) . RRV exhibit an amplification process that is inherent to the wild type virus life cycle, so while viral replication kinetics and lag times for exponential growth phase replication can vary, even a slower replication will allow progressive vector spread within a tumor until prodrug is given. We have previously demonstrated RRV replication and gene expression in subcutaneous mammary tumors (29) Figure   6C ). The MST of the group receiving the combined intratumoral effector alloCTL and RRV prodrug activator gene therapies (group 7) was 97.5 days, thus exhibiting a highly statistically significant survival benefit compared to each of the control groups ( Figure 6C) . Furthermore, the group receiving combined immune and gene therapies showed a statistically significant additional survival advantage compared to those groups receiving gene therapy alone (p<0.0001 and 0.0123, groups 7 vs. 6 and 5, respectively). The combination treatment also showed a trend toward statistical significance compared to the groups receiving alloCTL cellular therapy alone (p<0.0511 and 0.6380, groups 7 vs. 4 and 2, respectively).
As shown in
The individual animal weights of Figure 6 animals were monitored every 3-4 days and plotted over the duration of the experiment as one indication of treatment toxicity and/or morbidity due to tumor progression. The plots for the control groups, and the single or combined modality groups are shown starting on day 12 through 106 with prodrug cycle administration indicated on the abscissa (Supplemental Figure 1) . The plots not only show the extension of survival of animals in the experimental groups, but as well, indicate the health of the 11 long-term survivors present in groups 2, 4, 5, and 7. Except in sham-treated control animals (Groups 1 and 3), generally little to no weight loss occurred during or shortly after the first prodrug cycle and second alloCTL infusion.
Progressive weight loss at later time points was likely associated with higher tumor burden, and notably, stabilization or reversal of weight loss was observed following prodrug administration cycles in individual animals in Groups 2, 5, 6, and 7; this was most apparent after the last prodrug cycle in Groups 2 and 7, and most of those animals went on to thrive as indicated by stable or increasing weight gains. Thus, treatment with intracranial infusions of alloCTL as well as prodrug administration in RRV-CD treated animals both contributed positively to overall clinical response to therapy as measured by average body weight, and mice treated with combined immunogene therapy had the highest overall average weight throughout the course of treatment.
Histopathological findings of the brains from the long-term survivors (n=11, from Figure 6 experimental Groups 2, 4, 5 and 7) showed no evidence of tumor in H&E-stained sections, whereas there was consistent presence of tumor in animals that succumbed before the end of the survival experiment (Supplemental Figure 2) .
To monitor the spread of RRV-GFP or RRV-CD within the brain and to extratumoral sites, genomic DNA was extracted from brain/brain tumor, lung, liver, spleen, kidney, and bone marrow 
